Nonalcoholic Steatohepatitis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis, cardiovascular disease, and cancer. Physicians are limited to off-label therapies that have limited evidence to support prescribing. Consequently, there is a pressing need for new, effective drug treatments. With the launch of the first labeled / branded therapy on the horizon, we use claims data to examine how NASH is being treated in the United States among both newly diagnosed and recently treated patients.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed NASH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed NASH patients?
- How have off-label therapies, including Intercept Pharmaceuticals’ Ocaliva, been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of NASH patients receive off-label drug therapy within a year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
- What percentage of NASH patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Novo Nordisk, AstraZeneca, Eli Lilly, Johnson & Johnson, Boehringer Ingelheim, Merck, Intercept Pharmaceuticals
Key drugs: Ocaliva (obeticholic acid), pioglitazone, vitamin E, metformin, ursodeoxycholic acid, statins, SGLT-2 inhibitors, GLP-1 receptor agonists
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
Anuhya V., M.Pharm., is a research associate on the Cardiovascular, Metabolic, Renal, and Hematological Disorders team at Clarivate. She conducts extensive secondary market research for a variety of CMRH indications, including pulmonary hypertension (PH), nonalcoholic steatohepatitis (NASH), and heart failure (e.g., HFrEF, HFpEF). She holds a master’s degree in general pharmacy from BITS Pilani in India and a bachelor’s degree in pharmacy from G. Pulla Reddy College of Pharmacy, which is affiliated with Osmania University, in Hyderabad, India.